61 clinical trials
grid
list
download
Body (indexed field) | Identifiant (ID) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
28624 | 1. moderate or severe cGVHD per NIH Consensus Criteria 2. KPS score > 60%. 3. Evidence of myeloid and platelet engraftment, that is, ANC > 1.0 × 10e9/L and platelet count > 50 × 10e9/L. 4. Has not received more than 3 days/72 hours of systemic corticoster |
Sebastian Wittnebel | NA | Incyte Corporate | GRAVITAS-309 | Trial closed | A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309) | Sebastian.Wittnebel@hubruxelles.be | 2/3 | 2 | |
22646 | no suitable HLA-matched sibling or unrelated donor / no prior allogeneic stem cell transplantation/ AML, ALL or MDS | Philippe Lewalle | Multiple | Kiadis Pharma | HATCY study | Trial closed | A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy | philippe.lewalle@hubruxelles.be | 3 | 3 | |
28584 | IDH1 or IDH2 +, fit for standard chemotherapy | Sebastian Wittnebel | Acute leukemia | Hovon | HOVON 150 AML/ AMLSG 29-18 | Trial open for recruitment | A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy (HOVON 150 AML/ AMLSG 29-18) | Sebastian.Wittnebel@hubruxelles.be | 3 | 3 | |
29135 | Presence of the FLT3 mutation | Adriano Salaroli | Acute leukemia | Hovon | HOVON 156 AML / AMLSG 28-18 | Trial closed for recruitment | A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy | adriano.salaroli@hubruxelles.be | 3 | 3 | |
22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
29771 | RRMM: at least 2 prior lines of therapy with at least 2 consecutive cycles of a second or third generation immunomodulator (lenalidomide or pomalidomide), steroid (dexamethasone), proteasome inhibitor (bortezomib, carfilzoib, ixazomib) and anti-CD38 MoAb | Multiple | Sanofi-Aventis | IJB_3627 | Trial open for recruitment | A First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light[1]chain amyloidosis (RRLCA) | 1/2 | 1 | |||
29416 | Documented diagnosis of MM with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to IMiD (e.g., lenalidomide, pomalidomide) and PIs (e.g., bortezomib, carfilzomib, ixazomib) either alone or in combin | Nathalie Meuleman | Myeloma | Celyad | IMMUNICY-1 | Trial closed | An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease (IMMUNICY-1 - Immunotherapy for Multiple Myeloma with HLA-UNrestrIcted allogeneic CAR T-cell therapy CYAD-211) | nathalie.meuleman@hubruxelles.be | 1 | 1 | |
22655 | Any line | Ahmad Hussein Awada | Solid tumors | Incyte Corporate | INCB59872-101 | Trial closed | A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
22636 | Under Iclusig regimen | Philippe Lewalle | Multiple | Incyte Corporate | Incyte-30006 | Trial closed | Prospective Registry of Iclusig(r) (Ponatinib) used in Clinical Practice for the Treatment of Patients with Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | philippe.lewalle@hubruxelles.be | 4 | 4 | |
22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
22968 | Christiane Jungels | Multiple | iTeos | IO-002 | Trial closed | Phase I/IIa First-In_human Study of EOS884448 in Participants with Advanced Cancers | christiane.jungels@hubruxelles.be | 1/2 | 1 | ||
29650 | Patients with RRMM who have received at least one prior line of therapy ; for whom the treating physician has made the decision to initiate isatuximab per routine practice and independently of the purpose of the study | Nathalie Meuleman | Myeloma | Sanofi-Aventis | IONA | Trial open for recruitment | A non-interventional, multinational, observational study with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM)(OBS16577) IONA | nathalie.meuleman@hubruxelles.be | 4 | 4 |